NASDAQ:GNMK - GenMark Diagnostics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$6.82 +0.09 (+1.34 %)
(As of 02/22/2019 04:52 AM ET)
Previous Close$6.73
Today's Range$6.64 - $6.90
52-Week Range$3.58 - $8.81
Volume534,211 shs
Average Volume406,710 shs
Market Capitalization$381.61 million
P/E Ratio-5.64
Dividend YieldN/A
Beta1.49
GenMark Diagnostics, Inc., a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results. The company offers XT-8 instrument, and related diagnostic and research tests, as well as certain custom manufactured reagents that enable reference laboratories and hospitals to support a range of molecular tests with a workstation and disposable test cartridges. It also provides diagnostic tests for use with its XT-8 system that includes respiratory viral panel, cystic fibrosis genotyping test, thrombophilia risk test, a warfarin sensitivity test, and hepatitis C virus genotyping test and associated custom manufactured reagents, as well as 2C19 genotyping test. The company sells its products through direct sales and technically specialized service organization in the United States and Europe. GenMark Diagnostics, Inc. is headquartered in Carlsbad, California.

Receive GNMK News and Ratings via Email

Sign-up to receive the latest news and ratings for GNMK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GNMK
CUSIPN/A
Phone760-448-4300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$52.52 million
Book Value$1.29 per share

Profitability

Net Income$-61,850,000.00

Miscellaneous

Employees517
Market Cap$381.61 million
Next Earnings DateN/A
OptionableOptionable

GenMark Diagnostics (NASDAQ:GNMK) Frequently Asked Questions

What is GenMark Diagnostics' stock symbol?

GenMark Diagnostics trades on the NASDAQ under the ticker symbol "GNMK."

How were GenMark Diagnostics' earnings last quarter?

GenMark Diagnostics, Inc (NASDAQ:GNMK) issued its quarterly earnings results on Thursday, February, 21st. The medical equipment provider reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by $0.03. GenMark Diagnostics had a negative return on equity of 95.36% and a negative net margin of 79.33%. View GenMark Diagnostics' Earnings History.

What guidance has GenMark Diagnostics issued on next quarter's earnings?

GenMark Diagnostics issued an update on its FY 2019 earnings guidance on Thursday, February, 21st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $85-90 million, compared to the consensus revenue estimate of $86.66 million.

What price target have analysts set for GNMK?

5 brokers have issued twelve-month price objectives for GenMark Diagnostics' stock. Their forecasts range from $7.00 to $11.00. On average, they anticipate GenMark Diagnostics' share price to reach $9.50 in the next year. This suggests a possible upside of 39.3% from the stock's current price. View Analyst Price Targets for GenMark Diagnostics.

What is the consensus analysts' recommendation for GenMark Diagnostics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GenMark Diagnostics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GenMark Diagnostics.

Has GenMark Diagnostics been receiving favorable news coverage?

Press coverage about GNMK stock has trended positive this week, according to InfoTrie. The research group rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. GenMark Diagnostics earned a daily sentiment score of 2.3 on InfoTrie's scale. They also assigned news coverage about the medical equipment provider a news buzz of 8.0 out of 10, meaning that recent news coverage is very likely to have an effect on the company's share price in the immediate future.

Who are some of GenMark Diagnostics' key competitors?

What other stocks do shareholders of GenMark Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GenMark Diagnostics investors own include Mattel (MAT), General Electric (GE), Ultra Clean (UCTT), US Foods (USFD), Clear Channel Outdoor (CCO), Alibaba Group (BABA), American National BankShares (AMNB), New York Times (NYT), Twitter (TWTR) and Enterprise Bancorp (EBTC).

Who are GenMark Diagnostics' key executives?

GenMark Diagnostics' management team includes the folowing people:
  • Mr. Hany Massarany, CEO, Pres & Director (Age 58)
  • Mr. Scott Mendel, Chief Financial Officer (Age 52)
  • Mr. Michael Gleeson, Sr. VP of Corp. Accounts (Age 44)
  • Mr. Brian Andrew Mitchell, Sr. VP of Operations (Age 54)
  • Mr. Johnny Ek, VP of Fin. & Accounting and Corp. Controller

Who are GenMark Diagnostics' major shareholders?

GenMark Diagnostics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Casdin Capital LLC (6.82%), BlackRock Inc. (6.50%), Bellevue Group AG (3.57%), Bank of America Corp DE (2.15%), Penn Capital Management Co. Inc. (1.43%) and Northern Trust Corp (1.23%). Company insiders that own GenMark Diagnostics stock include Brian Andrew Mitchell, Eric Stier, Hany Massarany, James B Mcnally, Jennifer Anne Williams, John Frederick Ek, Jon Faiz Kayyem, Michael Gleeson, Michael Kagnoff and Scott Mendel. View Institutional Ownership Trends for GenMark Diagnostics.

Which institutional investors are selling GenMark Diagnostics stock?

GNMK stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Thrivent Financial for Lutherans, TD Asset Management Inc., Donaldson Capital Management LLC, MetLife Investment Advisors LLC, Royce & Associates LP, Two Sigma Advisers LP and Stephens Inc. AR. Company insiders that have sold GenMark Diagnostics company stock in the last year include Brian Andrew Mitchell, Eric Stier, Hany Massarany, James B Mcnally, Jennifer Anne Williams, John Frederick Ek, Michael Gleeson and Scott Mendel. View Insider Buying and Selling for GenMark Diagnostics.

Which institutional investors are buying GenMark Diagnostics stock?

GNMK stock was purchased by a variety of institutional investors in the last quarter, including Bellevue Group AG, Assenagon Asset Management S.A., Penn Capital Management Co. Inc., Casdin Capital LLC, Bank of America Corp DE, Rhumbline Advisers, Geode Capital Management LLC and BlackRock Inc.. View Insider Buying and Selling for GenMark Diagnostics.

How do I buy shares of GenMark Diagnostics?

Shares of GNMK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GenMark Diagnostics' stock price today?

One share of GNMK stock can currently be purchased for approximately $6.82.

How big of a company is GenMark Diagnostics?

GenMark Diagnostics has a market capitalization of $381.61 million and generates $52.52 million in revenue each year. The medical equipment provider earns $-61,850,000.00 in net income (profit) each year or ($1.21) on an earnings per share basis. GenMark Diagnostics employs 517 workers across the globe.

What is GenMark Diagnostics' official website?

The official website for GenMark Diagnostics is http://www.genmarkdx.com.

How can I contact GenMark Diagnostics?

GenMark Diagnostics' mailing address is 5964 LA PLACE COURT, CARLSBAD CA, 92008. The medical equipment provider can be reached via phone at 760-448-4300 or via email at [email protected]


MarketBeat Community Rating for GenMark Diagnostics (NASDAQ GNMK)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  379 (Vote Outperform)
Underperform Votes:  231 (Vote Underperform)
Total Votes:  610
MarketBeat's community ratings are surveys of what our community members think about GenMark Diagnostics and other stocks. Vote "Outperform" if you believe GNMK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNMK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel